ArticleJournal of translational medicine2025
Integrated analysis of blood microbiome and metabolites reveals key biomarkers and functional pathways in myocardial infarction.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gut Microbiome and Fecal Metabolome Analysis Reveal Potential Non-Invasive Biomarkers For Acute Myocardial Infarction.Probiotics and antimicrobial proteins · 2026Article
- The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease: From Mechanistic Insights to Precision Therapeutics.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Integrated oral microbiome and metabolome analysis unveils key biomarkers and functional pathway alterations in patients with acute myocardial infarction.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMyocardial infarction (MI) has been linked to changes in the blood microbiome, yet the interplay between microbiome and metabolome remains poorly understood. This study integrates blood microbiome profiling and metabolomic analysis to uncover biomarkers and pathways associated with MI.
methodsUsing 16 S rRNA sequencing and LC-MS metabolomics, blood samples from 24 MI patients and 24 healthy controls were analyzed. Microbial diversity, key taxa, metabolites, and their functional implications were evaluated.
resultsWhile alpha and beta diversity of the microbiome showed no significant differences, three bacterial taxa (Proteobacteria, Gammaproteobacteria, and Bacilli) and twenty metabolites (e.g., UPD-L-Ara4O, Urotensin-related peptide, and 9-hydroxy octadecanoic acid) were identified as potential biomarkers, achieving an AUC of 0.99-1. Functional pathway analysis revealed upregulation in glycerolipid metabolism and mTOR signaling pathways, which were significantly correlated with clinical markers of MI.
conclusionThis integrative approach highlights the diagnostic potential of blood microbiome-metabolome dynamics in MI and suggests mechanistic pathways that could guide future interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.